Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sarilumab use in severe SARS-CoV-2 pneumonia.
Gremese E, Cingolani A, Bosello SL, Alivernini S, Tolusso B, Perniola S, Landi F, Pompili M, Murri R, Santoliquido A, Garcovich M, Sali M, De Pascale G, Gabrielli M, Biscetti F, Montalto M, Tosoni A, Gambassi G, Rapaccini GL, Iaconelli A, Zileri Del Verme L, Petricca L, Fedele AL, Lizzio MM, Tamburrini E, Natalello G, Gigante L, Bruno D, Verardi L, Taddei E, Calabrese A, Lombardi F, Bernabei R, Cauda R, Franceschi F, Landolfi R, Richeldi L, Sanguinetti M, Fantoni M, Antonelli M, Gasbarrini A; GEMELLI AGAINST COVID-19 Group. Gremese E, et al. Among authors: tamburrini e. EClinicalMedicine. 2020 Oct;27:100553. doi: 10.1016/j.eclinm.2020.100553. Epub 2020 Oct 2. EClinicalMedicine. 2020. PMID: 33043284 Free PMC article.
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Di Giambenedetto S, et al. Among authors: tamburrini e. J Antimicrob Chemother. 2013 Jun;68(6):1364-72. doi: 10.1093/jac/dkt007. Epub 2013 Jan 30. J Antimicrob Chemother. 2013. PMID: 23372058
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection.
Fabbiani M, Di Giambenedetto S, Cingolani A, Fanti I, Colafigli M, Tamburrini E, Cauda R, Navarra P, De Luca A, Murri R. Fabbiani M, et al. Among authors: tamburrini e. Infect Dis (Lond). 2016;48(1):48-55. doi: 10.3109/23744235.2015.1082034. Epub 2015 Sep 2. Infect Dis (Lond). 2016. PMID: 26329383
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
Lombardi F, Belmonti S, Borghetti A, Fabbiani M, Marchetti S, Tamburrini E, Cauda R, di Giambenedetto S. Lombardi F, et al. Among authors: tamburrini e. J Antimicrob Chemother. 2020 Jun 1;75(6):1599-1603. doi: 10.1093/jac/dkaa058. J Antimicrob Chemother. 2020. PMID: 32101614
Off-label use of tocilizumab in patients with SARS-CoV-2 infection.
Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, Zileri Dal Verme L, Bernabei R, Tamburrini E, Cauda R, Gasbarrini A. Di Giambenedetto S, et al. Among authors: tamburrini e. J Med Virol. 2020 Oct;92(10):1787-1788. doi: 10.1002/jmv.25897. Epub 2020 Jun 29. J Med Virol. 2020. PMID: 32297987 Free PMC article. No abstract available.
Neonatal Late Onset Infection with Severe Acute Respiratory Syndrome Coronavirus 2.
Buonsenso D, Costa S, Sanguinetti M, Cattani P, Posteraro B, Marchetti S, Carducci B, Lanzone A, Tamburrini E, Vento G, Valentini P. Buonsenso D, et al. Among authors: tamburrini e. Am J Perinatol. 2020 Jun;37(8):869-872. doi: 10.1055/s-0040-1710541. Epub 2020 May 2. Am J Perinatol. 2020. PMID: 32359227 Free PMC article.
202 results